Silicon Investor
SI
SI

 Biotech / Medical : Biotech Valuation

 Public Reply | Prvt Reply | Mark as Last Read | FilePrevious 10 | Next 10 | Previous | Next  
To: Miljenko Zuanic who wrote (38119)4/16/2012 7:41:12 PM
From: BiomavenRead Replies (1) of 40322
 
>Aveo

>Was there any OS benefit in RCC?

Not yet disclosed.

> I am cautious that there is no off-target toxicity?

Seems to be a very targeted molecule. Hypertension is a class-effect and is quite predictive of efficacy.

Other side effects were markedly lower than any others in the class.

Seems cheap to me for the long term. Mostly the skepticism surrounds why Nexavar did so well, suggesting that these were "easy" patients somehow. The company says Nexavar results are not inconsistent with other trials. They also suggested at one point that there was some effect from the trial rules - patients couldn't cross over from Nexavar until there had been a centrally confirmed progression.

Peter
Report TOU ViolationShare This Post
 Public Reply | Prvt Reply | Mark as Last Read | FilePrevious 10 | Next 10 | Previous | Next  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQ
Copyright © 1995-2013 Knight Sac Media. All rights reserved.